Open AccessMolecular Markers In Forecasting The Clinical Efficacy Of Infliximab In Psoriasis Patients
Author(s) -
А. А. Кубанова,
I N Lesnaya,
Н В Фриго,
N L KAGANOVA,
L F ZNAMENSKAYA,
А. А. Кубанов
Publication year - 2010
Publication title -
vestnik dermatologii i venerologii
Language(s) - English
Resource type - Journals
eISSN - 2313-6294
pISSN - 0042-4609
DOI - 10.25208/vdv827
Subject(s) - psoriasis , infliximab , medicine , genotype , tumor necrosis factor alpha , locus (genetics) , immunology , cytokine , interleukin 10 , gastroenterology , interleukin , gene , biology , biochemistry
Biosamples (skin tissue samples taken from affection foci and blood serum) from 22 patients suffering from severe to medium psoriasis (8 women and 14 men) aged 19-57 treated with Infliximab were analyzed. As for skin tissue samples, the molecular structure of genes TNF-a, TNF-R-I and TNF-R-II, contents of cytokine TNF-a and its soluble receptors (sTNF-RI and sTNF-RII) and proteome composition was analyzed in skin tissue samples; contents of TNF-a, IL2, IL4, IL6, IL-8 and IL-10 were analyzed in the blood serum. The homozygous TT genotype of TNF-R-II gene at the 676 locus and high IL10 level in the blood serum (>2.7 pg/ml) was associated with the high intensity of the psoriasis patient response to treatment with Infliximab; the homozygous GG genotype of TNF-R-II gene at the 676 locus and low level of IL10 in the blood serum (